Effect of artificial pancreas system use on glycaemic control among pregnant women with type 1 diabetes mellitus: A meta‐analysis of randomized controlled trials

Abstract

AimTo assess the efficacy of artificial pancreas systems (APS) use among pregnant women with type 1 diabetes mellitus (T1DM) by conducting a meta‐analysis.MethodsWe searched five databases, including EMBASE, Web of Science, PubMed, Cochrane Library and SCOPUS, for literature on APS use among pregnant women with T1DM before October 9, 2023. The primary endpoint was 24‐hour time in range (TIR; 3.5‐7.8 mmol/L). Secondary endpoints included glycaemic metrics for 24‐hour (mean blood glucose [MBG], time above range [TAR], time below range [TBR]), and overnight TIR and TBR.ResultsWe identified four randomized controlled trials involving 164 participants; one study with 16 participants focused on overnight APS use, and the other three focused on 24‐hour APS use. Compared with standard care, APS exhibited a favourable effect on 24‐hour TIR (standard mean difference [SMD] = 0.53, 95% confidence interval [CI] 0.25, 0.80, P < 0.001), overnight TIR (SMD = 0.67, 95% CI 0.39, 0.95, P < 0.001), and overnight TBR (<3.5 mmol/L; SMD = −0.49, 95% CI −0.77, −0.21 P < 0.001), while there was no significant difference in 24‐hour TAR, 24‐hour TBR, or MBG between the two groups. We further conducted subgroup analyses after removing the trial focused on overnight APS use and showed that 24‐hour APS use reduced not only the 24‐hour TIR (SMD = 0.41, 95% CI 0.12, 0.71; P = 0.007) but also the 24‐hour TBR (<2.8 mmol/L; SMD = −0.77, 95% CI −1.32, −0.23, P = 0.006).ConclusionOur findings suggest that APS might improve 24‐hour TIR and overnight glycaemic control, and 24‐hour APS use also significantly reduced 24‐hour TBR (2.8 mmol/L) among pregnant women with T1DM.